56例乳腺癌新辅助化疗临床观察  

Neoadjuvant Chemotherapy for Breast Cancer:Clinical Observation of 56 Cases

作　　者：杨峥维[1] 张连平[1] 李佳[1] 

机构地区：[1]海军总医院药剂科,北京100037

出　　处：《中国现代医生》2009年第22期33-34,共2页China Modern Doctor

摘　　要：目的观察乳腺癌新辅助化疗的临床效果,并探讨其临床价值。方法对2006年5月～2008年4月收治的乳腺癌患者56例,予以新辅助化疗(ET方案)。2～4个周期后观察肿瘤、腋窝淋巴结的变化。结果新辅助化疗后临床完全缓解(CR)4例,部分缓解(PR)32例,共36例有效,有效率为64.3%;无疾病进展(PD)20例,占35.7%;腋窝淋巴结肿大者38例,临床CR8例,PR12例,有效率52.6%。结论新辅助化疗可有效缩小肿瘤原发病灶和腋窝淋巴结,降低肿瘤分期,为手术切除创造有利条件。Objective To observe the clinical effect of neoadjuvant chemotherapy for breast cancer and discuss the clinical value of the method. Methods We treated 56 patients with breast cancer by neoadjuvant chemotherapy from May 2006 to April 2008. We observed the changes of tumor and axillary lymph node after neoadjuvant chemotherapy. Results After neoadjuvant chemotherapy in patients with primary lesions,there was clinical complete remission in 4 cases and partial remission in 32 cases,with the overall response rate of 64.3%. There was clinical complete remission in 8 cases and partial remission in 12 cases in 38 patients with positive axillary lymph node,with the overall response rate of 52.6%. Conclusion Neoadjuvant chemotherapy can reduce the volume of primary lesion and the axillary lymph node and decrease the tumor stage, offering patients the favourable conditions for luther resection.

关 键 词：乳腺癌 新辅助化疗 临床观察 

分 类 号：R737.9[医药卫生—肿瘤]